2.19

3.30% 0.07

After Hours: 2.23 0.04 +1.83%

Caribou Biosciences Inc (CRBU)

Overview News Price History Option Chain Financials Why CRBU Down? Discussions Forecast

Caribou Biosciences Inc stock is traded at $2.19, with a volume of 1.85M. It is up +3.30% in the last 24 hours and up +16.49% over the past month. Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

Previous Close:

$2.12

Open:

$2.14

24h Volume:

1.85M

Relative Volume:

1.47

Market Cap:

$211.64M

Revenue:

$11.16M

Net Income/Loss:

$-148.13M

P/E Ratio:

-1.3787

EPS:

-1.5885

Net Cash Flow:

$-112.35M

1W Performance:

+12.31%

1M Performance:

+16.49%

6M Performance:

-22.89%

1Y Performance:

+181.09%

1-Day Range:

$2.13

$2.215

1-Week Range:

$1.90

$2.215

52-Week Range:

$0.71

$3.535

Caribou Biosciences Inc Stock (CRBU) Company Profile

Name

Caribou Biosciences Inc

Sector

Healthcare (1112)

Industry

Biotechnology (622)

Phone

510-982-6030

Address

2929 7TH STREET, SUITE 105, BERKELEY

Employee

Twitter

Next Earnings Date

Latest SEC Filings

CRBU's Discussions on Twitter

Compare CRBU vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRBU Caribou Biosciences Inc	2.19	204.87M	11.16M	-148.13M	-112.35M	-1.5885
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.85	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-03-24	Downgrade	Evercore ISI	Outperform → In-line
Nov-08-23	Initiated	Cantor Fitzgerald	Neutral
Oct-31-23	Initiated	Evercore ISI	Outperform
Jul-11-23	Initiated	Truist	Buy
Feb-18-22	Initiated	RBC Capital Mkts	Outperform
Dec-01-21	Initiated	Oppenheimer	Outperform
Nov-30-21	Initiated	H.C. Wainwright	Buy
Nov-15-21	Upgrade	Citigroup	Neutral → Buy
Aug-17-21	Initiated	BofA Securities	Buy
Aug-17-21	Initiated	Citigroup	Neutral
Aug-17-21	Initiated	SVB Leerink	Outperform

View All

Caribou Biosciences Inc Stock (CRBU) Latest News

Apr 11, 2026

Investment Recap: Should you avoid Caribou Biosciences Inc stock right now2026 Market WrapUp & AI Based Buy/Sell Signal Reports - baoquankhu1.vn

Apr 11, 2026

Apr 10, 2026

Caribou Biosciences (NASDAQ: CRBU) schedules virtual annual meeting June 17, 2026 - Stock Titan

Apr 10, 2026

CRBU News | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU) - ChartMill

Apr 10, 2026

Apr 08, 2026

CRBU Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 08, 2026

Apr 07, 2026

Caribou Biosciences' (CRBU) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Apr 07, 2026

H.C. Wainwright Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $9 - Moomoo

Apr 07, 2026

CRBU Forecast, Price Target & Analyst Ratings | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU) - ChartMill

Apr 07, 2026

Apr 06, 2026

Earnings Miss: How does Caribou Biosciences Inc compare to its peersWeekly Profit Report & Long-Term Capital Growth Strategies - baoquankhu1.vn

Apr 06, 2026

Apr 03, 2026

CRBU SEC FilingsCaribou Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 03, 2026